ZNF184 Inhibitors
Chemical inhibitors of ZNF184 can modulate the protein's function through various intracellular mechanisms. Palmitic Acid and 2-Bromopalmitate can directly affect ZNF184 by inhibiting the palmitoylation process. Palmitoylation often plays a crucial role in the proper localization and function of proteins, including those with zinc finger domains like ZNF184. By disrupting this post-translational modification, these inhibitors can lead to a reduction in ZNF184's activity within the cell. Similarly, ML-7 targets the cytoskeletal dynamics by inhibiting myosin light chain kinase, which may be essential for the correct localization of ZNF184 within the nucleus. On the other hand, PD 98059 and U0126 exert their effects by inhibiting MEK, which is part of the MAPK/ERK signaling pathway. Since this pathway can influence the activity of various transcription factors, its inhibition can result in a decrease in ZNF184's regulatory functions.
Furthermore, LY294002 and Wortmannin, both inhibitors of PI3K, can disrupt the cellular signaling pathways that are important for the regulatory environment of transcription factors like ZNF184. The inhibition of pathways involving PI3K can lead to an indirect reduction of ZNF184's activity. SB203580 and SP600125, which selectively inhibit p38 MAPK and JNK respectively, can prevent the phosphorylation that is required for the full functionality of ZNF184. PP2, a potent inhibitor of Src family kinases, can also interfere with signaling pathways that modulate transcription factor activity, including that of ZNF184. Additionally, Rapamycin's inhibition of mTOR can disrupt essential cellular processes such as growth and protein synthesis, which in turn can affect the function of ZNF184. Lastly, IKK Inhibitor XII targets the IKK complex involved in activating NF-κB; since NF-κB can regulate the expression and activity of a range of proteins, this inhibition could also impinge upon the functional capacity of ZNF184. Each of these chemical inhibitors, through their specific mechanisms, can lead to a decrease in the functional efficacy of ZNF184 within the cellular environment.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palmitic Acid | 57-10-3 | sc-203175 sc-203175A | 25 g 100 g | $112.00 $280.00 | 2 | |
Palmitic Acid can inhibit the palmitoylation of proteins. ZNF184, being a zinc finger protein, might require palmitoylation for proper function or localization, thus inhibition of palmitoylation would result in the functional inhibition of ZNF184. | ||||||
2-Bromohexadecanoic acid | 18263-25-7 | sc-251714 sc-251714A | 10 g 50 g | $52.00 $197.00 | 4 | |
2-Bromopalmitate is an inhibitor of protein palmitoylation. By inhibiting this post-translational modification, it may prevent the proper functioning of ZNF184 if palmitoylation is necessary for its activity. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML-7 inhibits myosin light chain kinase (MLCK), which could affect cytoskeletal dynamics. Since transcription factors like ZNF184 may rely on intact cytoskeletal networks for nuclear localization, ML-7 may inhibit ZNF184 function by disrupting its localization. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 inhibits MEK, which is upstream of ERK. ZNF184, through its zinc finger domains, may interact with substrates or structures regulated by the ERK pathway; inhibition of this pathway may therefore inhibit ZNF184's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K. PI3K is involved in numerous cellular processes, including those that could impact the function of transcription factors. By inhibiting PI3K, LY294002 may indirectly inhibit ZNF184 function by altering its regulatory environment. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAPK, which might be involved in phosphorylation events that regulate transcription factors. Inhibition of p38 MAPK may thus inhibit ZNF184 by preventing its required phosphorylation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which may regulate transcription factors by phosphorylation. Inhibiting JNK may prevent necessary phosphorylation of ZNF184, thus inhibiting its function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a potent inhibitor of Src family kinases. These kinases can influence signaling pathways that modulate transcription factor activity. Inhibition by PP2 may thus disrupt signaling required for ZNF184 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, which are part of the MAPK/ERK pathway. As transcription factors like ZNF184 may require this pathway for function or localization, functional inhibition of ZNF184 could occur as a result of U0126 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an inhibitor of PI3K, which is involved in the regulation of various transcription factors. ZNF184 could be functionally inhibited by wortmannin due to alterations in the cellular pathways necessary for its activity. | ||||||